Syntach AB

Key People

• Patrick NJ Schnegelsberg - Chief Executive Officer
• Cansel Isikli - Vice President of Regulatory and Quality Affairs

Assessment

Team

Aspect: 1 successful MedTech entrepreneur
Summary: Experienced leadership with a track record in MedTech.

The CEO, Patrick NJ Schnegelsberg, has over two decades of industry experience, including roles at Occlutech Group and other MedTech startups. The VP of Regulatory and Quality Affairs, Cansel Isikli, has 15 years of experience in medical device R&D and regulatory affairs, previously serving as VP R&D at Occlutech Group.

Clinical Need

Aspect: Very Strong
Summary: Addresses a significant unmet need in heart failure treatment.

Over 64 million people suffer from heart failure globally. Syntach's Cardiac Support system provides a minimally invasive solution that avoids open-heart surgery, potentially improving patient outcomes and quality of life.

Competition

Aspect: Somewhat crowded
Summary: Competing in a market with existing solutions but offering unique advantages.

The cardiac assist device market includes several established companies. However, Syntach's minimally invasive approach and focus on enhancing natural heart movement differentiate it from traditional left ventricular assist devices (LVADs).

Technical Challenge

Aspect: Complex
Summary: Developing a novel implantable device with advanced features.

Creating a fully implantable, battery-powered cardiac support device that enhances the atrioventricular plane's movement requires overcoming substantial technical and biological hurdles, including device miniaturization, biocompatibility, and long-term reliability.

Patent

Aspect: Applied
Summary: Patent status not specified in available sources.

The available information does not specify the patent status of Syntach's technologies. Further research is needed to assess the strength and scope of their intellectual property portfolio.

Financing

Aspect: Well-funded
Summary: Secured significant funding from the European Innovation Council.

Syntach AB has been awarded up to 17.5 million in blended funding from the European Innovation Council, including a 2.5 million grant and up to 15 million in equity financing, to advance the development of their Cardiac Support system.

Regulatory

Aspect: Concept Stage
Summary: Early stages of regulatory approval process.

Syntach's products are currently under development and have not received regulatory approval for clinical use. The company has partnered with Meditrial, a clinical research organization, to support their clinical and regulatory strategies.

Opportunity Rollup

Odds of Success

4.05

Peak Market Share

5.7

Segment CAGR

5.8%

Market Segment

Cardiac Assist Devices

Market Sub Segment

<em>Unknown</em>

Key Takeaway

Syntach AB is developing a minimally invasive cardiac support device addressing a significant unmet need in heart failure treatment, backed by experienced leadership and substantial funding.